Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (243)

« Back to Publications

Phase II multicentre double-blind randomised controlled trial of a Bivalent VaccInation against Salmonella Typhi and Paratyphi A (BiVISTA) using a controlled human infection model of paratyphoid A infection: study protocol.

Paganotti Vicentine M. et al, (2026), BMJ Open, 16

It never rains but pours: disseminated nocardiosis in a renal transplant patient from Nigeria - a case report.

Whitehead T. et al, (2025), BMC Infect Dis, 26

Safety, Efficacy, and Immunogenicity of a Salmonella Paratyphi A Vaccine.

McCann N. et al, (2025), N Engl J Med, 393, 1704 - 1714

Diagnostic Accuracy of 3 Mpox Lateral Flow Assays for Antigen Detection, Democratic Republic of the Congo and United Kingdom.

Ishara-Nshombo E. et al, (2025), Emerg Infect Dis, 31, 1140 - 1148

T cell memory response to MPXV infection exhibits greater effector function and migratory potential compared to MVA-BN vaccination.

Chen J-L. et al, (2025), Nat Commun, 16

The tear production of tecovirimat in a single hospitalized mpox patient: a pharmacokinetic analysis.

Woolley SD. et al, (2025), J Antimicrob Chemother, 80, 1455 - 1457

R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.

Venkatraman N. et al, (2025), Lancet Microbe, 6

Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.

Venkatraman N. et al, (2025), Lancet Microbe, 6

SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir.

Singh K. et al, (2024), J Infect Dis, 230, 624 - 634

MAVMET trial: maraviroc and/or metformin for metabolic dysfunction associated fatty liver disease in adults with suppressed HIV.

McCabe L. et al, (2024), AIDS, 38, 1513 - 1522

Author Correction: Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses.

Michael BD. et al, (2024), Nat Commun, 15

Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease.

Liew F. et al, (2024), Nat Immunol, 25, 607 - 621

Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT).

Paton NI. et al, (2024), EClinicalMedicine, 69

Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses.

Michael BD. et al, (2023), Nat Commun, 14

Anomalies in the review process and interpretation of the evidence in the NICE guideline for chronic fatigue syndrome and myalgic encephalomyelitis.

White P. et al, (2023), J Neurol Neurosurg Psychiatry, 94, 1056 - 1063

Load More

1
2
3
4
5
6
7
...
»